

Robert S Brown

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6329077/publications.pdf>

Version: 2024-02-01

199
papers

14,184
citations

34076

52
h-index

20943

115
g-index

212
all docs

212
docs citations

212
times ranked

14050
citing authors

#	ARTICLE	IF	CITATIONS
1	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i> , 2018, 67, 1560-1599.	3.6	2,620
2	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	0.6	725
3	Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. <i>Hepatology</i> , 2014, 59, 1144-1165.	3.6	717
4	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <i>American Journal of Transplantation</i> , 2020, 20, 1800-1808.	2.6	683
5	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019, 575, 505-511.	13.7	493
6	A Survey of Liver Transplantation from Living Adult Donors in the United States. <i>New England Journal of Medicine</i> , 2003, 348, 818-825.	13.9	475
7	Thrombocytopenia associated with chronic liver disease. <i>Journal of Hepatology</i> , 2008, 48, 1000-1007.	1.8	463
8	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 284-306.	3.6	414
9	An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. <i>New England Journal of Medicine</i> , 2014, 371, 2375-2382.	13.9	377
10	Hepatitis C and liver transplantation. <i>Nature</i> , 2005, 436, 973-978.	13.7	319
11	Sofosbuvir and Ribavirin for Treatment of Compensated Recurrent Hepatitis C Virus Infection After Liver Transplantation. <i>Gastroenterology</i> , 2015, 148, 108-117.	0.6	317
12	Sofosbuvir and Ribavirin Prevent Recurrence of HCV Infection After Liver Transplantation: An Open-Label Study. <i>Gastroenterology</i> , 2015, 148, 100-107.e1.	0.6	307
13	Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. <i>Hepatology</i> , 2007, 46, 971-981.	3.6	289
14	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 319-333.	3.6	275
15	Clinical risk factors for portopulmonary hypertension. <i>Hepatology</i> , 2008, 48, 196-203.	3.6	239
16	Improvement in Survival Associated With Adult-to-Adult Living Donor Liver Transplantation. <i>Gastroenterology</i> , 2007, 133, 1806-1813.	0.6	216
17	Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. <i>Liver Transplantation</i> , 2002, 8, 278-284.	1.3	189
18	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. <i>Hepatology</i> , 2011, 54, 91-100.	3.6	188

#	ARTICLE	IF	CITATIONS
19	Update on Prevention, Diagnosis, and Treatment of Chronic Hepatitis B: AASLD 2018 Hepatitis B Guidance. <i>Clinical Liver Disease</i> , 2018, 12, 33-34.	1.0	187
20	Prevalence of HBV precore/core promoter variants in the United States. <i>Hepatology</i> , 2003, 38, 619-628.	3.6	185
21	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018, 68, 1298-1307.	3.6	158
22	Steroid use in acute liver failure. <i>Hepatology</i> , 2014, 59, 612-621.	3.6	153
23	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 71, 522-538.	3.6	151
24	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , 2017, 66, 1090-1101.	3.6	149
25	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018, 69, 396-405.	1.8	144
26	Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. <i>Hepatology</i> , 2014, 59, 1073-1083.	3.6	138
27	Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. <i>Hepatology</i> , 2011, 54, 1313-1321.	3.6	136
28	Scope of worldwide hepatitis C problem. <i>Liver Transplantation</i> , 2003, 9, S10-S13.	1.3	124
29	Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 122-129.	1.3	119
30	Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. <i>Liver Transplantation</i> , 2003, 9, 1028-1035.	1.3	116
31	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013, 57, 1752-1762.	3.6	113
32	Standing the test of time: Outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. <i>Hepatology</i> , 2014, 60, 1957-1962.	3.6	110
33	Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1 and 6 and compensated cirrhosis: The EXPEDITION-8 trial. <i>Journal of Hepatology</i> , 2020, 72, 441-449.	1.8	109
34	Extracorporeal cellular therapy (ELAD) in severe alcoholic hepatitis: A multinational, prospective, controlled, randomized trial. <i>Liver Transplantation</i> , 2018, 24, 380-393.	1.3	101
35	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016, 22, 24-33.	1.3	100
36	Sorafenib: Where do we go from here?. <i>Hepatology</i> , 2010, 52, 360-369.	3.6	92

#	ARTICLE	IF	CITATIONS
37	The Survival Impact of Liver Transplantation in the MELD Era, and the Future for Organ Allocation and Distribution. <i>American Journal of Transplantation</i> , 2005, 5, 203-204.	2.6	88
38	Is it Time to Abandon the Milan Criteria?. <i>Annals of Surgery</i> , 2018, 268, 690-699.	2.1	87
39	Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). <i>Journal of Hepatology</i> , 2015, 62, 346-353.	1.8	85
40	A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. <i>Journal of Hepatology</i> , 2014, 61, 508-514.	1.8	75
41	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020, 72, 2182-2196.	3.6	74
42	Five-Year Outcomes of Endoscopic Sleeve Gastropasty for the Treatment of Obesity. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1051-1057.e2.	2.4	72
43	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: Findings from the Antiretroviral Pregnancy Registry. <i>Journal of Hepatology</i> , 2012, 57, 953-959.	1.8	71
44	Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1. <i>Hepatology</i> , 2007, 46, 982-990.	3.6	70
45	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020, 40, 1841-1852.	1.9	66
46	Early clinical experience with nirmatrelvir/ritonavir for the treatment of COVID-19 in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 2083-2088.	2.6	64
47	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 122-132.	3.7	63
48	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. <i>Hepatology</i> , 2016, 63, 307-318.	3.6	62
49	Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. <i>Cancer</i> , 2010, 116, 1801-1809.	2.0	60
50	Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: A worldwide study. <i>Journal of Hepatology</i> , 2021, 75, 1026-1033.	1.8	59
51	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2678-2687.	3.0	55
52	One-year morbidity after donor right hepatectomy. <i>Liver Transplantation</i> , 2004, 10, 1428-1431.	1.3	54
53	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants. <i>American Journal of Transplantation</i> , 2022, 22, 1925-1926.	2.6	54
54	Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. <i>Liver Transplantation</i> , 2011, 17, 409-417.	1.3	53

#	ARTICLE	IF	CITATIONS
55	Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 903-906.e1.	2.4	47
56	Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. <i>Hepatology</i> , 2021, 74, 1523-1532.	3.6	47
57	Improvement in insulin resistance and estimated hepatic steatosis and fibrosis after endoscopic sleeve gastroplasty. <i>Gastrointestinal Endoscopy</i> , 2021, 93, 1110-1118.	0.5	45
58	A Review of the Current State of Liver Transplantation Disparities. <i>Liver Transplantation</i> , 2021, 27, 434-443.	1.3	44
59	Serotonin Transporter Polymorphisms in Patients With Portopulmonary Hypertension. <i>Chest</i> , 2009, 135, 1470-1475.	0.4	38
60	Management of Thrombocytopenia in Patients with Chronic Liver Disease. <i>Digestive Diseases and Sciences</i> , 2019, 64, 2757-2768.	1.1	38
61	COVID-19 therapeutics and outcomes among solid organ transplant recipients during the Omicron BA.1 era. <i>American Journal of Transplantation</i> , 2022, 22, 2682-2688.	2.6	35
62	Dynamic Î±-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2021, 156, 559.	2.2	34
63	Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool. <i>PLoS ONE</i> , 2020, 15, e0239536.	1.1	33
64	Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 1357-1365.	1.3	32
65	Health-related quality of life and survival in liver transplant candidates. <i>Liver Transplantation</i> , 2010, 16, 238-245.	1.3	32
66	Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. <i>Liver Transplantation</i> , 2003, 9, 254-259.	1.3	29
67	Association of Search Query Interest in Gastrointestinal Symptoms With COVID-19 Diagnosis in the United States: Infodemiology Study. <i>JMIR Public Health and Surveillance</i> , 2020, 6, e19354.	1.2	28
68	Sorafenib in Hepatopulmonary Syndrome: A Randomized, Double-blind, Placebo-controlled Trial. <i>Liver Transplantation</i> , 2019, 25, 1155-1164.	1.3	26
69	Obesity and Microvascular Invasion in Hepatocellular Carcinoma. <i>Cancer Investigation</i> , 2010, 28, 1063-1069.	0.6	25
70	The North American Consortium for the Study of End-stage Liver Disease's Acute-on-Chronic Liver Failure Score Accurately Predicts Survival: An External Validation Using a National Cohort. <i>Liver Transplantation</i> , 2020, 26, 187-195.	1.3	25
71	The Current Management of Hepatorenal Syndrome—Acute Kidney Injury in the United States and the Potential of Terlipressin. <i>Liver Transplantation</i> , 2021, 27, 1191-1202.	1.3	23
72	Early Paracentesis in High-Risk Hospitalized Patients: Time for a New Quality Indicator. <i>American Journal of Gastroenterology</i> , 2019, 114, 1863-1869.	0.2	21

#	ARTICLE	IF	CITATIONS
73	Liver and Kidney Recipient Selection of Hepatitis C Virus Viremic Donors: Meeting Consensus Report From the 2019 Controversies in Transplantation. <i>Transplantation</i> , 2020, 104, 476-481.	0.5	20
74	Risk factors for hepatocellular carcinoma (HCC) in the northeast of the United States: results of a case-control study. <i>Cancer Causes and Control</i> , 2020, 31, 321-332.	0.8	20
75	Effect of rifaximin on infections, acute and chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH). <i>Liver International</i> , 2022, 42, 1109-1120.	1.9	20
76	Elevated CA19-9 Is Associated With Increased Mortality In A Prospective Cohort Of Hepatocellular Carcinoma Patients. <i>Clinical and Translational Gastroenterology</i> , 2015, 6, e74.	1.3	18
77	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 1-4.	3.6	18
78	Cholangiocarcinoma. <i>Clinics in Liver Disease</i> , 2020, 24, 421-436.	1.0	17
79	Trajectory of Serum Bilirubin Predicts Spontaneous Recovery in a Real-World Cohort of Patients With Alcoholic Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e289-e297.	2.4	17
80	Clinical, histological and molecular profiling of different stages of alcohol-related liver disease. <i>Gut</i> , 2022, 71, 1856-1866.	6.1	17
81	Cost Effectiveness of Early Insertion of Transjugular Intrahepatic Portosystemic Shunts for Recurrent Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 1503-1510.e3.	2.4	16
82	Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. <i>Clinical Transplantation</i> , 2018, 32, e13415.	0.8	16
83	Predictors of Candidate Maturation Among Potential Living Donors. <i>American Journal of Transplantation</i> , 2005, 5, 2549-2554.	2.6	15
84	Postpartum care for mothers diagnosed with hepatitis B during pregnancy. <i>American Journal of Obstetrics and Gynecology</i> , 2015, 212, 365.e1-365.e7.	0.7	15
85	Cirrhosis as a Comorbidity in Conditions Subject to the Hospital Readmissions Reduction Program. <i>American Journal of Gastroenterology</i> , 2019, 114, 1488-1495.	0.2	15
86	Role of the Independent Donor Advocacy Team in Ethical Decision Making. <i>Progress in Transplantation</i> , 2005, 15, 298-302.	0.4	14
87	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , 2017, 30, 196-208.	0.8	14
88	Daclatasvir and sofosbuvir treatment of decompensated liver disease or post-liver transplant hepatitis C virus recurrence in patients with advanced liver disease/cirrhosis in a real-world cohort. <i>Hepatology Communications</i> , 2018, 2, 354-363.	2.0	14
89	SARS-CoV-2 infection increases tacrolimus concentrations in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, e14193.	0.8	14
90	Overt Hepatic Encephalopathy: Current Pharmacologic Treatments and Improving Clinical Outcomes. <i>American Journal of Medicine</i> , 2021, 134, 1330-1338.	0.6	14

#	ARTICLE	IF	CITATIONS
91	Medicaid Expansion Association With End-Stage Liver Disease Mortality Depends on Leniency of Medicaid Hepatitis C Virus Coverage. <i>Liver Transplantation</i> , 2021, 27, 1723-1732.	1.3	14
92	Predictors of donor follow-up after living donor liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 967-976.	1.3	13
93	A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. <i>Hepatology</i> , 2019, 70, 1038-1044.	3.6	13
94	National Trends in Location of Death in Patients With End-Stage Liver Disease. <i>Liver Transplantation</i> , 2021, 27, 165-176.	1.3	13
95	American Gastroenterological Association Institute Technical Review on Initial Testing and Management of Acute Liver Disease. <i>Gastroenterology</i> , 2017, 152, 648-664.e5.	0.6	12
96	Ascites Neutrophil Gelatinase-Associated Lipocalin Identifies Spontaneous Bacterial Peritonitis and Predicts Mortality in Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2017, 62, 3487-3494.	1.1	12
97	Oral Cyanobacteria and Hepatocellular Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 221-229.	1.1	12
98	One-Year Outcomes of the Multi-Center Study to Transplant Hepatitis C-Infected kidneys (MYTHIC) Trial. <i>Kidney International Reports</i> , 2022, 7, 241-250.	0.4	12
99	Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts. <i>Liver Transplantation</i> , 2018, 24, 881-887.	1.3	11
100	Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?. <i>Hepatology</i> , 2020, 71, 4-7.	3.6	11
101	Uncontrolled diabetes mellitus increases risk of infection in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , 2021, 53, 445-451.	0.4	11
102	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. <i>Liver International</i> , 2018, 38, 1010-1021.	1.9	10
103	Can Living Donor Liver Transplantation in the United States Reach Its Potential?. <i>Liver Transplantation</i> , 2021, 27, 1644-1652.	1.3	10
104	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019, 3, 1388-1399.	2.0	9
105	Genetic Causes of Liver Disease. <i>Medical Clinics of North America</i> , 2019, 103, 991-1003.	1.1	9
106	Identifying Risk of Alcohol Relapse After Liver Transplantation: What Tools Do We Need?. <i>Liver Transplantation</i> , 2019, 25, 1133-1135.	1.3	9
107	Plasma levels of S100A4 in portopulmonary hypertension. <i>Biomarkers</i> , 2009, 14, 156-160.	0.9	8
108	Postpartum Laboratory Follow-up in Women With Hepatitis B in Massachusetts From 2007 to 2012. <i>Journal of Clinical Gastroenterology</i> , 2016, 50, e60-e64.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Genetic Testing in Liver Disease. <i>Clinics in Liver Disease</i> , 2017, 21, 673-686.	1.0	8
110	Peripartum Care for Mothers Diagnosed with Hepatitis B During Pregnancy: A Survey of Provider Practices. <i>Maternal and Child Health Journal</i> , 2018, 22, 1345-1351.	0.7	8
111	Nonviral or Drug-Induced Etiologies of Acute Liver Failure. <i>Clinics in Liver Disease</i> , 2018, 22, 347-360.	1.0	8
112	IDDF2019-ABS-0210â€¦Preliminary efficacy and safety of 8-week glecaprevir/pibrentasvir in patients with HCV genotype 1â€“6 infection and compensated cirrhosis: the EXPEDITION-8 study. , 2019, , .		8
113	Association Between Kidney Dysfunction Types and Mortality Among Hospitalized Patients with Cirrhosis. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3426-3435.	1.1	8
114	Asymptomatic Liver Mass. <i>Gastroenterology</i> , 2006, 131, 619-623.	0.6	7
115	Quality improvement initiative increases total paracentesis and early paracentesis rates in hospitalised cirrhotics with ascites. <i>Frontline Gastroenterology</i> , 2020, 11, 22-27.	0.9	7
116	Assessing the periprocedural magnitude of platelet count change in response to lusutrombopag. <i>JHEP Reports</i> , 2021, 3, 100228.	2.6	7
117	Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3363-3370.	1.4	7
118	Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 1328-1336.	1.3	6
119	Less bleeding associated with apixaban versus other direct acting oral anticoagulation in solid organ transplant recipients. <i>Clinical Transplantation</i> , 2021, 35, .	0.8	6
120	Customizing treatment to patient populations. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2007, 4, S3-S9.	1.7	5
121	Patient Perspectives of Highâ€“Quality Care on the Liver Transplant Waiting List: A Qualitative Study. <i>Liver Transplantation</i> , 2020, 26, 238-246.	1.3	5
122	Identification of Quantifiable Predictors of Relapse in Patients with Alcoholâ€“Associated Liver Disease. <i>Hepatology Communications</i> , 2021, 5, 1156-1164.	2.0	5
123	Hepatology Highlights. <i>Hepatology</i> , 2021, 74, 1-4.	3.6	5
124	Practices and Perceptions of Living Donor Liver Transplantation, Nondirected Donation, and Liver Paired Exchange: A National Survey. <i>Liver Transplantation</i> , 2022, 28, 774-781.	1.3	5
125	Should patients with chronic hepatitis c who have normal alt levels be treated?. <i>Current Gastroenterology Reports</i> , 2001, 3, 49-53.	1.1	4
126	Discovery of diffuse biliary microhamartomas during liver procurement. <i>Liver Transplantation</i> , 2007, 13, 1470-1471.	1.3	4

#	ARTICLE	IF	CITATIONS
127	Liver Transplantation for the Referring Physician. <i>Clinics in Liver Disease</i> , 2015, 19, 135-153.	1.0	4
128	HCV Council "critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016, 36, 488-502.	1.9	4
129	Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018, 39, 566-577.	0.8	4
130	The clinical and economic burden of patients with chronic liver disease and thrombocytopenia receiving platelet transfusions during planned invasive procedures. <i>GastroHep</i> , 2019, 1, 236-248.	0.3	4
131	Peripartum Maternal Hepatitis B Care in a US Nationwide Data Set. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, e424-e430.	1.1	4
132	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021, 27, 1382-1391.	1.3	4
133	Pharmacokinetics of tacrolimus co-administered with adefovir dipivoxil to liver transplant recipients. <i>Liver International</i> , 2009, 29, 1178-1183.	1.9	2
134	Pathophysiologic basis for the medical management of portal hypertension. <i>Expert Opinion on Pharmacotherapy</i> , 2009, 10, 453-467.	0.9	2
135	Hepatology Highlights. <i>Hepatology</i> , 2019, 70, 1497-1499.	3.6	2
136	Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020, 44, 2307-2315.	1.4	2
137	Hepatology Highlights. <i>Hepatology</i> , 2020, 71, 1-3.	3.6	2
138	An Evidence-based Practical Guide to Vaccination for Hepatitis B Virus. <i>Journal of Clinical Gastroenterology</i> , 2022, Publish Ahead of Print, .	1.1	2
139	Optimizing pre-donation physiologic evaluation for enhanced recovery after living liver donation "Systematic review and multidisciplinary expert panel recommendations. <i>Clinical Transplantation</i> , 2022, , e14680.	0.8	2
140	The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015, 8, 263-269.	1.4	1
141	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 2311-2314.	3.6	1
142	Hepatology Highlights. <i>Hepatology</i> , 2019, 69, 1365-1368.	3.6	1
143	Hepatology Highlights. <i>Hepatology</i> , 2021, 73, 2085-2088.	3.6	1
144	A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. <i>Gastroenterology and Hepatology</i> , 2017, 13, 154-163.	0.2	1

#	ARTICLE	IF	CITATIONS
145	A New Hope for a New Year. Liver Transplantation, 2022, 28, 7-8.	1.3	1
146	Efficacy and Safety of 8- or 12 Weeks of Glecaprevir/Pibrentasvir in Patients with Evidence of Portal Hypertension. Infectious Diseases and Therapy, 2022, 11, 913-924.	1.8	1
147	Persistence of Virologic Response after Liver Transplant in Hepatitis C Patients Treated with Ledipasvir / Sofosbuvir Plus Ribavirin Pretransplant. Annals of Hepatology, 2017, 16, 375-381.	0.6	1
148	Sociodemographic characteristics of living liver donors: Few changes over 20 years. Clinical Transplantation, 2022, 36, e14701.	0.8	1
149	WIN-R revisited: Response to editorial. Hepatology, 2008, 47, 1427-1427.	3.6	0
150	The Risk of Hepatocellular Carcinoma in Patients with Previous Malignancy. Cancer Investigation, 2008, 26, 511-515.	0.6	0
151	Viral hepatitis and renal failure. Current Hepatitis Reports, 2009, 8, 119-126.	0.3	0
152	Diagnostic utility of chromosome 17 and p16 abnormalities in fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology, 2010, 52, 393-394.	3.6	0
153	Hepatitis B and Liver Transplantation: Update in Management before and after Transplantation. Current Hepatitis Reports, 2011, 10, 255-261.	0.3	0
154	Hepatitis C viral infection after liver transplantation. Clinical Liver Disease, 2012, 1, 73-76.	1.0	0
155	Reply. Hepatology, 2014, 60, 1448-1448.	3.6	0
156	Reply. Hepatology, 2015, 61, 1439-1439.	3.6	0
157	Reply. Hepatology, 2015, 62, 1328-1329.	3.6	0
158	HE or not HE? That is Frequently the Question. Clinics in Liver Disease, 2015, 19, xi-xii.	1.0	0
159	Reply. Hepatology, 2016, 64, 1824-1825.	3.6	0
160	Treatment of hepatitis C virus in advanced renal disease. Clinical Liver Disease, 2017, 10, 79-81.	1.0	0
161	Hepatology Highlights. Hepatology, 2018, 67, 817-819.	3.6	0
162	Hepatology Highlights. Hepatology, 2018, 67, 1647-1650.	3.6	0

#	ARTICLE	IF	CITATIONS
163	Hepatology Highlights. Hepatology, 2018, 67, 1195-1197.	3.6	0
164	Hepatology Highlights. Hepatology, 2018, 67, 461-463.	3.6	0
165	Geographic Areas of Liver Distribution in the United States Should Not Be Redesigned According to the 2016 Eightâ€œDistrict Organ Procurement and Transplantation Network Proposal. Clinical Liver Disease, 2018, 12, 65-67.	1.0	0
166	If hepatitis C therapy is so great, why isn't everyone doing it?. American Journal of Transplantation, 2018, 18, 2382-2383.	2.6	0
167	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. Current Hepatology Reports, 2019, 18, 363-369.	0.4	0
168	Details Make the Difference: The Important Need to Accurately Understand the Cost-Effectiveness of Transjugular Intrahepatic Portosystemic Shunts in Patients with Ascites. Journal of Vascular and Interventional Radiology, 2019, 30, 1310-1311.	0.2	0
169	Hepatology Highlights. Hepatology, 2019, 69, 469-472.	3.6	0
170	Acute HCV Treatment: What Should We Do in the DAA Era?. Current Hepatology Reports, 2019, 18, 216-221.	0.4	0
171	Hepatology Highlights. Hepatology, 2019, 69, 1849-1851.	3.6	0
172	Hepatology Highlights. Hepatology, 2019, 69, 927-930.	3.6	0
173	Hepatology Highlights. Hepatology, 2019, 70, 1881-1884.	3.6	0
174	Hepatology Highlights. Hepatology, 2020, 72, 791-793.	3.6	0
175	Hepatology Highlights. Hepatology, 2020, 72, 369-370.	3.6	0
176	Hepatology Highlights. Hepatology, 2020, 72, 1893-1896.	3.6	0
177	Hepatology Highlights. Hepatology, 2020, 72, 1505-1508.	3.6	0
178	Hepatology Highlights. Hepatology, 2020, 71, 771-773.	3.6	0
179	Hepatology Highlights. Hepatology, 2020, 71, 405-407.	3.6	0
180	Hepatology Highlights. Hepatology, 2020, 71, 1527-1529.	3.6	0

#	ARTICLE	IF	CITATIONS
181	Hepatology Highlights. Hepatology, 2020, 71, 1143-1145.	3.6	0
182	A New Year, A New Team. Liver Transplantation, 2021, 27, 7-8.	1.3	0
183	Hepatology Highlights. Hepatology, 2021, 73, 1-3.	3.6	0
184	Hepatology Highlights. Hepatology, 2021, 73, 475-478.	3.6	0
185	Reply. Liver Transplantation, 2021, 27, 606-606.	1.3	0
186	Hepatology Highlights. Hepatology, 2021, 73, 1245-1247.	3.6	0
187	Hepatology Highlights. Hepatology, 2021, 74, 539-542.	3.6	0
188	Hepatology Highlights. Hepatology, 2021, 74, 1137-1140.	3.6	0
189	Protecting Patients With Cirrhosis From Coronavirus Disease 2019: Identifying Gaps in Vaccination Rates. Liver Transplantation, 2021, 27, 1535-1537.	1.3	0
190	Hepatology Highlights. Hepatology, 2021, 74, 1727-1729.	3.6	0
191	Hepatology Highlights. Hepatology, 2021, 74, 2329-2332.	3.6	0
192	HCV and Liver Transplantation. Current Hepatology Reports, 0, , 1.	0.4	0
193	Hepatitis C and Liver Transplantation in the Era of New Antiviral Treatments. , 2018, , 239-262.		0
194	Regional, racial/ethnic, and socioeconomic disparities and treatment outcomes in patients with hepatocellular carcinoma (HCC) in the United States.. Journal of Clinical Oncology, 2019, 37, 424-424.	0.8	0
195	Current and emerging therapies for chronic hepatitis B: a review of selected presentations from the 2010 meeting of the European association for the study of the liver april 14-18, 2010 vienna, austria. Gastroenterology and Hepatology, 2010, 6, 1-8.	0.2	0
196	Hepatology Highlights. Hepatology, 2021, 74, 2931-2934.	3.6	0
197	The Dark Before Dawn. Liver Transplantation, 2022, 28, 533-534.	1.3	0
198	Introducing the Certificate of Added Qualification (CAQ) Corner. Liver Transplantation, 2022, 28, 1127-1127.	1.3	0

#	ARTICLE	IF	CITATIONS
199	Deceased donor liver transplantation in patients on direct oral anticoagulants at the time of transplant surgery: A case series. Liver Transplantation, 0, , .	1.3	0